Tags

ED after prostate cancer treatment

Posted in September 5th, 2009
Published in Efficacy

All of the available prostate cancer treatments, including radical prostatectomy, external beam radiation therapy, brachytherapy, cryotherapy, androgen-deprivation therapy, and even active surveillance alone, can result in ED. ED after prostate cancer treatment includes both organic and psychogenic causes, as significant anxiety and depression may result from a diagnosis of prostate cancer, leading to psychogenic ED. […]

read more from " ED after prostate cancer treatment "

ED secondary to diabetes mellitus

Posted in September 1st, 2009
Published in Efficacy

ED is a common problem afflicting over a third of all men with diabetes mellitus type 2, and diabetes is independently responsible for a 3- to 4-fold increase in the risk of ED according to a survey of 1460 diabetic men. ED is strongly related to the severity of diabetes, with a higher incidence in […]

read more from " ED secondary to diabetes mellitus "

Difficult-to-treat ED

Posted in August 20th, 2009
Published in Efficacy

In the two trials mentioned in the previous section, the patient population was largely a primary care population of relatively healthy men with ED of varying severities and etiologies. To the contrary, a multicentered, randomized, double-blind, placebo controlled trial evaluated how tadalafil 20 mg improved ED in men presenting to tertiary care centers with more […]

read more from " Difficult-to-treat ED "

The general ED population

Posted in August 15th, 2009
Published in Efficacy

The most frequently referenced study supporting the efficacy of tadalafil is an integrated analysis of 5 randomized, double-blind, placebo controlled, multicentered phase III trials from 1112 men at 74 centers worldwide. The average age was 59, and the etiology of ED was 61% organic, 9% psychogenic, and 31% mixed. The ED severity at baseline was […]

read more from " The general ED population "

Duration of action

Posted in August 14th, 2009
Published in Pharmacology
Tags: ED, PDE5, tadalafil

Among the three PDE5 inhibitors, the half-life and thus duration of action is the pharmacologic parameter that is the most strikingly dissimilar. The half-life of tadalafil is 17.5 hours in normal healthy men and 21.6 hours in elderly men, while the half-lives of sildenafil and vardenafil are similar at 4 hours. This longer half-life provides […]

read more from " Duration of action "

Background on outcome measures

Posted in August 6th, 2009
Published in Efficacy
Tags: ED, IIEF, PDE5, SEP, tadalafil

Although the effectiveness of PDE5 inhibitors on such intermediate objective outcomes as penile rigidity through penile plethysmography with the RigiScan device (Dacomed Corporation, Minneapolis, MN, USA) has been studied, measuring the therapeutic effectiveness of tadalafil (Cialis Professional) is more accurately defined through an integration of the patient’s reported treatment response and tolerability with the reported […]

read more from " Background on outcome measures "

Efficacy of Tadalafil

Posted in July 11th, 2009
Published in Efficacy
Tags: ED, tadalafil

Tadalafil is an efficacious treatment for ED of all severities and etiologies. The largest data series exist for the general ED population with mild to moderate ED, but tadalafil has also been shown to be an effective treatment for difficult-to-treat ED such as more severe, organic ED evaluated in tertiary care centers, ED secondary to […]

read more from " Efficacy of Tadalafil "